{"id":52710,"date":"2023-01-09T18:02:17","date_gmt":"2023-01-09T17:02:17","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/maat-pharma-half-year-report-on-liquidity-contract-with-the-brokerage-firm-kepler-cheuvreux\/"},"modified":"2023-01-09T18:02:17","modified_gmt":"2023-01-09T17:02:17","slug":"maat-pharma-half-year-report-on-liquidity-contract-with-the-brokerage-firm-kepler-cheuvreux","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/maat-pharma-half-year-report-on-liquidity-contract-with-the-brokerage-firm-kepler-cheuvreux\/","title":{"rendered":"MaaT Pharma: Half-year Report on Liquidity Contract With the Brokerage Firm Kepler Cheuvreux"},"content":{"rendered":"<div>\n<p>LYON, France&#8211;(BUSINESS WIRE)&#8211;<a href=\"https:\/\/twitter.com\/search?q=%24MAAT&amp;src=ctag\" target=\"_blank\" rel=\"noopener\">$MAAT<\/a>&#8212;<span class=\"bwuline\"><b><a target=\"_blank\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.maatpharma.com%2F&amp;esheet=53180043&amp;newsitemid=20230109005558&amp;lan=en-US&amp;anchor=MaaT+Pharma&amp;index=1&amp;md5=1e7a370a6a3b0403902800c648cfab37\" rel=\"nofollow noopener\" shape=\"rect\">MaaT Pharma<\/a><\/b><\/span> <b>(EURONEXT: MAAT \u2013 the \u201cCompany\u201d), a French clinical-stage biotech and a pioneer in the development of Microbiome Ecosystem Therapies<sup>TM<\/sup> (MET) dedicated to improving survival outcomes for patients with cancer, <\/b>today announces its half-year report on the liquidity contract with the brokerage firm Kepler Cheuvreux.\n<\/p>\n<p><a href=\"https:\/\/mms.businesswire.com\/media\/20230109005558\/en\/729326\/5\/Nov_2018_new_version_MaaT_Pharma_logo.jpg\"><img decoding=\"async\" src=\"https:\/\/mms.businesswire.com\/media\/20230109005558\/en\/729326\/21\/Nov_2018_new_version_MaaT_Pharma_logo.jpg\"><\/a><\/p>\n<p>\nUnder the liquidity contract entered between MaaT Pharma and Kepler Cheuvreux, the following resources appeared on the liquidity account on December 31<sup>st<\/sup>, 2022:\n<\/p>\n<ul class=\"bwlistdisc \">\n<li>\n12,507 shares\n<\/li>\n<li>\n\u20ac63,045.61\n<\/li>\n<\/ul>\n<p class=\"bwmarginl1\">\n&#8211; Number of executions on buy side on semester: 390\n<\/p>\n<p class=\"bwmarginl1\">\n&#8211; Number of executions on sell side on semester: 330\n<\/p>\n<p class=\"bwmarginl1\">\n&#8211; Traded volume on buy side on semester: 14,188 shares for \u20ac131,237.39\n<\/p>\n<p class=\"bwmarginl1\">\n&#8211; Traded volume on sell side on semester: 9,342 shares for \u20ac86,141.84\n<\/p>\n<p>\nAs a reminder:\n<\/p>\n<ul class=\"bwlistdisc\">\n<li>\nthe following resources appeared on the last half year statement on 30 June 2022 on the liquidity account:\n<\/li>\n<\/ul>\n<ul class=\"bwlistdisc bwmarginl1\">\n<li>\n7,661 shares\n<\/li>\n<li>\n\u20ac108,063.69\n<\/li>\n<\/ul>\n<p class=\"bwmarginl1\">\n&#8211; Number of executions on buy side on semester: 244\n<\/p>\n<p class=\"bwmarginl1\">\n&#8211; Number of executions on sell side on semester: 134\n<\/p>\n<p class=\"bwmarginl1\">\n&#8211; Traded volume on buy side on semester: 12,600 shares for \u20ac153,377.30\n<\/p>\n<p class=\"bwmarginl1\">\n&#8211; Traded volume on sell side on semester: 4,939 shares for \u20ac61,676.96\n<\/p>\n<ul class=\"bwlistdisc\">\n<li>\nthe following resources appeared on the liquidity account when the activity started:\n<\/li>\n<\/ul>\n<ul class=\"bwlistdisc bwmarginl1\">\n<li>\n0 shares\n<\/li>\n<li>\n\u20ac200,000.00\n<\/li>\n<\/ul>\n<p>\nThe implementation of this report is carried out in accordance with AMF Decision N\u00b02021-01 of June 22<sup>nd<\/sup>, 2021, renewing the implementation of liquidity contracts for shares as an accepted market practice.\n<\/p>\n<p>\n<b>About MaaT Pharma<\/b>\n<\/p>\n<p>\nMaaT Pharma, a clinical stage biotechnology company, has established a complete approach to restoring patient-microbiome symbiosis in oncology. Committed to treating cancer and graft-versus-host disease (GvHD), a serious complication of allogeneic stem cell transplantation, MaaT Pharma has already achieved proof of concept in a Phase II clinical trial in acute GvHD. Our powerful discovery and analysis platform, gutPrint\u00ae, supports the development and expansion of our pipeline by determining novel disease targets, evaluating drug candidates, and identifying biomarkers for microbiome-related conditions.\n<\/p>\n<p>\nThe company\u2019s Microbiome Ecosystem Therapies are produced through a standardized cGMP manufacturing and quality control process to safely deliver the full diversity of the microbiome, in liquid and oral formulations. MaaT Pharma benefits from the commitment of world-leading scientists and established relationships with regulators to support the integration of the use of microbiome therapies in clinical practice.\n<\/p>\n<p>\nMaaT Pharma is listed on Euronext Paris (ticker: MAAT).\n<\/p>\n<p> <b>Contacts<\/b> <\/p>\n<p>\n<b>MaaT Pharma<\/b><br \/>Herv\u00e9 AFFAGARD<br \/>\n<br \/>Co-Founder and CEO<br \/>\n<br \/>Si\u00e2n CROUZET, COO\/ CFO<br \/>\n<br \/>+33 4 28 29 14 00<br \/>\n<br \/><a target=\"_blank\" href=\"&#x6d;&#x61;&#105;lt&#x6f;&#x3a;&#105;&#110;v&#x65;&#x73;&#116;&#64;m&#x61;&#x61;&#x74;&#45;ph&#x61;&#x72;&#109;&#97;&#46;&#x63;&#x6f;&#109;\" rel=\"nofollow noopener\" shape=\"rect\">&#x69;n&#x76;&#101;&#x73;&#116;&#64;&#x6d;&#97;&#x61;&#116;-&#x70;&#104;&#x61;&#114;m&#x61;&#46;&#x63;&#111;&#x6d;<\/a>\n<\/p>\n<p>\n<b>MaaT Pharma<\/b><br \/>Pauline RICHAUD<br \/>\n<br \/>Senior PR &amp; Corporate Communications Manager<br \/>\n<br \/>+33 6 07 55 25 36<br \/>\n<br \/><a target=\"_blank\" href=\"&#109;&#x61;i&#108;&#x74;o&#58;&#x70;r&#x69;&#x63;&#104;&#x61;u&#100;&#x40;m&#97;&#x61;t&#x2d;&#x70;&#104;&#x61;&#x72;&#109;&#x61;&#46;&#99;&#x6f;m\" rel=\"nofollow noopener\" shape=\"rect\">&#x70;&#x72;&#x69;&#x63;&#x68;&#x61;&#117;&#100;&#64;&#109;aat-&#x70;&#x68;&#x61;&#x72;&#x6d;&#x61;&#46;&#99;&#111;&#109;<\/a>\n<\/p>\n<p>\n<b>Trophic Communications<br \/>\n<br \/>Corporate Communications<\/b><br \/>Jacob VERGHESE or<br \/>\n<br \/>Gretchen SCHWEITZER<br \/>\n<br \/>+49 89 23 88 77 31<br \/>\n<br \/><a target=\"_blank\" href=\"m&#97;&#105;&#x6c;&#x74;o:&#109;&#97;&#x61;&#x74;&#64;t&#114;&#111;&#x70;&#x68;ic&#46;&#x65;&#x75;\" rel=\"nofollow noopener\" shape=\"rect\">maat&#64;&#116;&#114;&#111;&#112;&#104;&#105;&#x63;&#x2e;&#x65;&#x75;<\/a>\n<\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"<p>LYON, France&#8211;(BUSINESS WIRE)&#8211;$MAAT&#8212;MaaT Pharma (EURONEXT: MAAT \u2013 the \u201cCompany\u201d), a French clinical-stage biotech and a pioneer in the development of Microbiome Ecosystem TherapiesTM (MET) dedicated to improving survival outcomes for patients with cancer, today announces its half-year report on the liquidity contract with the brokerage firm Kepler Cheuvreux. Under the liquidity contract entered between MaaT &#8230; <span class=\"more\"><a class=\"more-link\" href=\"https:\/\/pharma-trend.com\/en\/maat-pharma-half-year-report-on-liquidity-contract-with-the-brokerage-firm-kepler-cheuvreux\/\">[Read more&#8230;]<\/a><\/span><\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[13],"tags":[],"class_list":{"0":"entry","1":"post","2":"publish","3":"author-business","4":"post-52710","6":"format-standard","7":"category-industry"},"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.5 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>MaaT Pharma: Half-year Report on Liquidity Contract With the Brokerage Firm Kepler Cheuvreux - Pharma Trend<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pharma-trend.com\/en\/maat-pharma-half-year-report-on-liquidity-contract-with-the-brokerage-firm-kepler-cheuvreux\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"MaaT Pharma: Half-year Report on Liquidity Contract With the Brokerage Firm Kepler Cheuvreux - Pharma Trend\" \/>\n<meta property=\"og:description\" content=\"LYON, France&#8211;(BUSINESS WIRE)&#8211;$MAAT&#8212;MaaT Pharma (EURONEXT: MAAT \u2013 the \u201cCompany\u201d), a French clinical-stage biotech and a pioneer in the development of Microbiome Ecosystem TherapiesTM (MET) dedicated to improving survival outcomes for patients with cancer, today announces its half-year report on the liquidity contract with the brokerage firm Kepler Cheuvreux. Under the liquidity contract entered between MaaT ... [Read more...]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pharma-trend.com\/en\/maat-pharma-half-year-report-on-liquidity-contract-with-the-brokerage-firm-kepler-cheuvreux\/\" \/>\n<meta property=\"og:site_name\" content=\"Pharma Trend\" \/>\n<meta property=\"article:published_time\" content=\"2023-01-09T17:02:17+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mms.businesswire.com\/media\/20230109005558\/en\/729326\/21\/Nov_2018_new_version_MaaT_Pharma_logo.jpg\" \/>\n<meta name=\"author\" content=\"Business Wire\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Business Wire\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/maat-pharma-half-year-report-on-liquidity-contract-with-the-brokerage-firm-kepler-cheuvreux\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/maat-pharma-half-year-report-on-liquidity-contract-with-the-brokerage-firm-kepler-cheuvreux\\\/\"},\"author\":{\"name\":\"Business Wire\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\"},\"headline\":\"MaaT Pharma: Half-year Report on Liquidity Contract With the Brokerage Firm Kepler Cheuvreux\",\"datePublished\":\"2023-01-09T17:02:17+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/maat-pharma-half-year-report-on-liquidity-contract-with-the-brokerage-firm-kepler-cheuvreux\\\/\"},\"wordCount\":418,\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/maat-pharma-half-year-report-on-liquidity-contract-with-the-brokerage-firm-kepler-cheuvreux\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20230109005558\\\/en\\\/729326\\\/21\\\/Nov_2018_new_version_MaaT_Pharma_logo.jpg\",\"articleSection\":[\"Industry\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/maat-pharma-half-year-report-on-liquidity-contract-with-the-brokerage-firm-kepler-cheuvreux\\\/\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/maat-pharma-half-year-report-on-liquidity-contract-with-the-brokerage-firm-kepler-cheuvreux\\\/\",\"name\":\"MaaT Pharma: Half-year Report on Liquidity Contract With the Brokerage Firm Kepler Cheuvreux - Pharma Trend\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/maat-pharma-half-year-report-on-liquidity-contract-with-the-brokerage-firm-kepler-cheuvreux\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/maat-pharma-half-year-report-on-liquidity-contract-with-the-brokerage-firm-kepler-cheuvreux\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20230109005558\\\/en\\\/729326\\\/21\\\/Nov_2018_new_version_MaaT_Pharma_logo.jpg\",\"datePublished\":\"2023-01-09T17:02:17+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/maat-pharma-half-year-report-on-liquidity-contract-with-the-brokerage-firm-kepler-cheuvreux\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/pharma-trend.com\\\/en\\\/maat-pharma-half-year-report-on-liquidity-contract-with-the-brokerage-firm-kepler-cheuvreux\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/maat-pharma-half-year-report-on-liquidity-contract-with-the-brokerage-firm-kepler-cheuvreux\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20230109005558\\\/en\\\/729326\\\/21\\\/Nov_2018_new_version_MaaT_Pharma_logo.jpg\",\"contentUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20230109005558\\\/en\\\/729326\\\/21\\\/Nov_2018_new_version_MaaT_Pharma_logo.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/maat-pharma-half-year-report-on-liquidity-contract-with-the-brokerage-firm-kepler-cheuvreux\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"MaaT Pharma: Half-year Report on Liquidity Contract With the Brokerage Firm Kepler Cheuvreux\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"name\":\"Pharma Trend\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\",\"name\":\"Pharma Trend\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"\",\"contentUrl\":\"\",\"caption\":\"Pharma Trend\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\",\"name\":\"Business Wire\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"MaaT Pharma: Half-year Report on Liquidity Contract With the Brokerage Firm Kepler Cheuvreux - Pharma Trend","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pharma-trend.com\/en\/maat-pharma-half-year-report-on-liquidity-contract-with-the-brokerage-firm-kepler-cheuvreux\/","og_locale":"en_US","og_type":"article","og_title":"MaaT Pharma: Half-year Report on Liquidity Contract With the Brokerage Firm Kepler Cheuvreux - Pharma Trend","og_description":"LYON, France&#8211;(BUSINESS WIRE)&#8211;$MAAT&#8212;MaaT Pharma (EURONEXT: MAAT \u2013 the \u201cCompany\u201d), a French clinical-stage biotech and a pioneer in the development of Microbiome Ecosystem TherapiesTM (MET) dedicated to improving survival outcomes for patients with cancer, today announces its half-year report on the liquidity contract with the brokerage firm Kepler Cheuvreux. Under the liquidity contract entered between MaaT ... [Read more...]","og_url":"https:\/\/pharma-trend.com\/en\/maat-pharma-half-year-report-on-liquidity-contract-with-the-brokerage-firm-kepler-cheuvreux\/","og_site_name":"Pharma Trend","article_published_time":"2023-01-09T17:02:17+00:00","og_image":[{"url":"https:\/\/mms.businesswire.com\/media\/20230109005558\/en\/729326\/21\/Nov_2018_new_version_MaaT_Pharma_logo.jpg","type":"","width":"","height":""}],"author":"Business Wire","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Business Wire","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pharma-trend.com\/en\/maat-pharma-half-year-report-on-liquidity-contract-with-the-brokerage-firm-kepler-cheuvreux\/#article","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/maat-pharma-half-year-report-on-liquidity-contract-with-the-brokerage-firm-kepler-cheuvreux\/"},"author":{"name":"Business Wire","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24"},"headline":"MaaT Pharma: Half-year Report on Liquidity Contract With the Brokerage Firm Kepler Cheuvreux","datePublished":"2023-01-09T17:02:17+00:00","mainEntityOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/maat-pharma-half-year-report-on-liquidity-contract-with-the-brokerage-firm-kepler-cheuvreux\/"},"wordCount":418,"publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/maat-pharma-half-year-report-on-liquidity-contract-with-the-brokerage-firm-kepler-cheuvreux\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20230109005558\/en\/729326\/21\/Nov_2018_new_version_MaaT_Pharma_logo.jpg","articleSection":["Industry"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/pharma-trend.com\/en\/maat-pharma-half-year-report-on-liquidity-contract-with-the-brokerage-firm-kepler-cheuvreux\/","url":"https:\/\/pharma-trend.com\/en\/maat-pharma-half-year-report-on-liquidity-contract-with-the-brokerage-firm-kepler-cheuvreux\/","name":"MaaT Pharma: Half-year Report on Liquidity Contract With the Brokerage Firm Kepler Cheuvreux - Pharma Trend","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/maat-pharma-half-year-report-on-liquidity-contract-with-the-brokerage-firm-kepler-cheuvreux\/#primaryimage"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/maat-pharma-half-year-report-on-liquidity-contract-with-the-brokerage-firm-kepler-cheuvreux\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20230109005558\/en\/729326\/21\/Nov_2018_new_version_MaaT_Pharma_logo.jpg","datePublished":"2023-01-09T17:02:17+00:00","breadcrumb":{"@id":"https:\/\/pharma-trend.com\/en\/maat-pharma-half-year-report-on-liquidity-contract-with-the-brokerage-firm-kepler-cheuvreux\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pharma-trend.com\/en\/maat-pharma-half-year-report-on-liquidity-contract-with-the-brokerage-firm-kepler-cheuvreux\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/maat-pharma-half-year-report-on-liquidity-contract-with-the-brokerage-firm-kepler-cheuvreux\/#primaryimage","url":"https:\/\/mms.businesswire.com\/media\/20230109005558\/en\/729326\/21\/Nov_2018_new_version_MaaT_Pharma_logo.jpg","contentUrl":"https:\/\/mms.businesswire.com\/media\/20230109005558\/en\/729326\/21\/Nov_2018_new_version_MaaT_Pharma_logo.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/pharma-trend.com\/en\/maat-pharma-half-year-report-on-liquidity-contract-with-the-brokerage-firm-kepler-cheuvreux\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/pharma-trend.com\/en\/"},{"@type":"ListItem","position":2,"name":"MaaT Pharma: Half-year Report on Liquidity Contract With the Brokerage Firm Kepler Cheuvreux"}]},{"@type":"WebSite","@id":"https:\/\/pharma-trend.com\/en\/#website","url":"https:\/\/pharma-trend.com\/en\/","name":"Pharma Trend","description":"","publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pharma-trend.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/pharma-trend.com\/en\/#organization","name":"Pharma Trend","url":"https:\/\/pharma-trend.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/","url":"","contentUrl":"","caption":"Pharma Trend"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24","name":"Business Wire"}]}},"_links":{"self":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/52710","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/comments?post=52710"}],"version-history":[{"count":0,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/52710\/revisions"}],"wp:attachment":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/media?parent=52710"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/categories?post=52710"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/tags?post=52710"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}